Lumos Pharma Inc

Lumos Pharma — FY2022 Earnings Presentation

8 slides from Lumos Pharma's earnings presentation, Mar 1, 2023

  1. Slide 1: Full Year 2022 Financial Results & Clinical Update

    1 Full Year 2022 Financial Results & Clinical Update March 1, 2023

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation contains proprietary and confidential information of Lumos Pharma, Inc. (“Lumos,” “we,” “us” and “our”), and such content should be considered “Confidential Information” and covered by your confidentiality obligations to Lumos. This presentation is made

  3. Slide 3: Agenda

    3 Agenda • Lisa Miller, Senior Director of Investor Relations • Rick Hawkins, Chief Executive Officer & Chairman • Rick Hawkins, Chief Executive Officer & Chairman • John McKew, PhD, President & Chief Scientific Officer • David B. Karpf, MD, Chief Medical Officer • Lori Lawley, Chief Financial Offic

  4. Slide 4: Highlights: OraGrowtH210 and OraGrowtH212 Trials Completed Enrollment

    4 Highlights OraGrowtH210 and OraGrowtH212 Trials Completed Enrollment • 82 PEM+ PGHD subjects randomized • Phase 2 trial – multiple sites • 4 treatment arms o 0.8 mg/kg/day LUM-201 o 1.6 mg/kg/day LUM-201 o 3.2 mg/kg/day LUM-201 o Standard dose rhGH control arm • Primary outcome at 6 months on ther

  5. Slide 5: Interim OraGrowtH Trials Analysis: LUM-201 Met Expectations in Idiopathic PGHD

    5 Interim OraGrowtH Trials Analysis: LUM-201 Met Expectations in Idiopathic PGHD SAEs = Serious adverse events AEs = Adverse events • AHV of 8.6 cm at 6-months on 1.6 mg/kg/day LUM-201, in line with 8.3 cm expected in PEM+ PGHD • LUM-201 AHVs are sustained & converge with rhGH AHVs at 12-month treat

  6. Slide 6: Additional Highlights

    6 Additional Highlights • Oral Presentation: Dose-dependent Increase in GH AUC0-12h with LUM-201 in Idiopathic Pediatric GH Deficiency (iPGHD) from the Interim Analysis Data of the OraGrowtH212 Trial • Poster Presentation: Baseline Demographics of the OraGrowtH210 Trial Studying LUM-201 in Idiopathi

  7. Slide 7: Lumos Pharma Financial Information as of December 31, 2022

    7 Lumos Pharma Financial Information as of December 31, 2022 Values in USD Cash $67.4M Debt $0 Shares Outstanding 8.3M Cash Use per Quarter in 2023 $9.5-$10.5M Fiscal Year End December 31 LUMO Cash balance to support current operations into 3Q 2024, Beyond primary outcome data readouts for OraGrowtH

  8. Slide 8: Investment Highlights Summary

    8 Investment Highlights Summary Novel Oral Rare Disease Asset • Novel oral therapeutic asset, LUM-201, for growth hormone deficiency (GHD) disorders • Potential to disrupt significant subset of sizable injectable market for GHD Late-stage Trials in PGHD • Enrollment completed for Phase 2 OraGrowtH21

Lumos Pharma — FY2022 Earnings Presentation on 6ix